BIOMARKERS FOR PREDICTING PROSTATE CANCER PROGRESSION

• Main Authors: HSIEH, SHIHUAN, TSAI, CHIN-HSIEN, TZENG, SHEUE-FEN, LEE, MING-SHYUE, HSIAO, PEI-WEN
• Format: Patent
• Language: English; French
• Published: 12.12.2019
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PHYSICS; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; TESTING; VINEGAR; WINE

The present invention relates to biomarkers, methods and assay kits for predicting prognosis and/or monitoring progression of prostate cancer. The biomarkers include a glycosyltransferases [core 1 beta-3-galactosyltransferase (C1GALT1) and/or ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3GAL1)] gene product, its saccharide substrate/product, and/or a galectin-4 gene product. La présente invention concerne des biomarqueurs, des procédés et des kits de dosage pour prédire le pronostic et/ou surveiller la progression du cancer de la prostate. Les biomarqueurs comprennent un produit génique glycosyltransférases [noyau 1 beta-3-galactosyltransférase (C1GALT1) et/ou ST3 Beta-galactoside alpha -2,3-sialyltransférase 1 (ST3GAL1)], son substrat/produit saccharidique et/ou un produit génique galectine -4.